Orchestra BioMed Holdings (OBIO) Current Deferred Revenue (2021 - 2025)

Orchestra BioMed Holdings (OBIO) has 5 years of Current Deferred Revenue data on file, last reported at $4.6 million in Q3 2025.

• Quarterly Current Deferred Revenue rose 14.34% year-over-year to $4.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $4.6 million (up 14.34% YoY) and the FY2024 annual result came in at $4.4 million, up 76.85% from the prior year.
• Current Deferred Revenue grew to $4.6 million in Q3 2025 per OBIO's latest filing, from $4.5 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $22.4 million in Q4 2021 and bottomed at $2.5 million in Q4 2023.
• The 5-year median for Current Deferred Revenue is $4.4 million (2023), against an average of $7.7 million.
• Peak annual rise in Current Deferred Revenue reached 76.85% in 2024, while the deepest fall reached 83.42% in 2024.
• Tracing OBIO's Current Deferred Revenue over 5 years: stood at $22.4 million in 2021, then slumped by 71.27% to $6.4 million in 2022, then tumbled by 61.0% to $2.5 million in 2023, then jumped by 76.85% to $4.4 million in 2024, then advanced by 4.73% to $4.6 million in 2025.
• Per Business Quant, the three latest OBIO Current Deferred Revenue figures stand at $4.6 million (Q3 2025), $4.5 million (Q2 2025), and $3.9 million (Q1 2025).

Peer Comparison